CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.
Quinn T Ostrom, Mackenzie Price, Corey Neff...
https://pubmed.ncbi.nlm.nih.gov/36196752Actively Recruiting
Phase Not Applicable
Age: 15Years - 120Years
All Genders
ID07374692
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
Led by National Cancer Institute (NCI) · Updated on 2026-05-22
80
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary central nervous system (CNS) tumors, which include recurrent gliomas and other rare brain tumors, are challenging to treat and often have poor outcomes. This research evaluates a new AI-driven technology called SmartMatch, developed to analyze how tumor tissue samples respond to various FDA-approved drugs. The goal is to see if SmartMatch can provide drug response results within 21 days after tumor tissue is collected to help doctors explore better treatment options for patients with advanced CNS tumors. During the study, participants who are scheduled for tumor biopsy or surgery at NIH will have small tumor samples collected as part of their planned procedure. These fresh samples will be analyzed using the SmartMatch platform to generate drug response data. Blood samples will also be collected for additional molecular profiling. The study does not require any extra procedures beyond what is planned for clinical care. Participants will be followed remotely every six months for up to three years to monitor their health and any disease progression. The research team will review how quickly and effectively the SmartMatch platform completes the drug screen analysis and will gather molecular information about the tumors over time. The study aims to improve understanding of CNS tumors and support the development of more precise treatments in the future.
CONDITIONS
Brief Title
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
Who Can Participate
Age: 15Years - 120Years
All Genders
Eligibility Criteria
You may qualify if you...
- Participants must have advanced CNS tumors confirmed by a documented pathology report, including recurrent IDH-wild-type high-grade glioma, recurrent IDH-mutant gliomas, or other recurrent CNS tumors
- Participants must be scheduled for brain tumor biopsy or resection at NIH
- Scheduled biopsy or resection must be at least 6 months after any prior radiation therapy, if applicable
- Age 15 years or older
- Ability to understand and sign informed consent by participant or legally authorized representative
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility confirmation and informed consent
Tumor Sample Collection
Duration - Day of planned biopsy or resection
Participants undergo a planned brain tumor biopsy or resection at NIH to collect fresh tumor samples for SmartMatch drug screen analysis and molecular profiling.
1 visit (in-person) for tumor biopsy or resection
Remote Follow-up
Duration - Up to 3 years
Participants are followed remotely every 6 (+/-3) months for up to 3 years to monitor outcomes after tumor sample collection.
Remote follow-up every 6 months (+/- 3 months)
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Loading map...
Research Team
C
Christine T McGowan
J
Jing Wu, M.D.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Challenges to curing primary brain tumours.
Kenneth Aldape, Kevin M Brindle, Louis Chesler...
https://pubmed.ncbi.nlm.nih.gov/30733593Measuring Real-time Drug Response in Organotypic Tumor Tissue Slices.
Nao Nishida-Aoki, Andrew J Bondesson, Taranjit S Gujral
https://pubmed.ncbi.nlm.nih.gov/32420994